Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | KYNU | Q16719 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56919 | 0.89 | CTSL (0.43) | KYNUELANECTSKTACR1CTSL | |
| SCHEMBL56738 | 0.87 | HDAC1 (0.46) | MAPTCTSL | |
| SCHEMBL56757 | 0.82 | HDAC1 (0.51) | CTSL | |
| SCHEMBL21189192 | 0.81 | KYNU (0.58) | KYNUELANEPRTN3CTSKTACR1 | |
| SCHEMBL21174053 | 0.81 | KYNU (0.58) | KYNUELANEPRTN3CTSKTACR1 | |
| SCHEMBL57018 | 0.79 | CTSL (0.48) | KYNUELANEPRTN3CTSKCTSL | |
| SCHEMBL56582 | 0.79 | ALDH1A1 (0.43) | KYNUELANEPOLBCTSL | |
| SCHEMBL21174062 | 0.78 | TACR1 (0.53) | KYNUELANECTSKTACR1CTSL | |
| SCHEMBL21174049 | 0.78 | TACR1 (0.53) | KYNUELANECTSKTACR1CTSL | |
| SCHEMBL56432 | 0.78 | TACR1 (0.53) | KYNUELANECTSKTACR1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008137446-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASE | TRUSTEES OF BOSTON UNIVERSITY (US) | 2008-11-13 | — | — | WO | claimed |
| US-8129557-B2 | Phosphonic acid diester derivative and method for producing thereof | Nagai, Kazuhiro (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090163725-A1 | PHOSPHONIC ACID DIESTER DERIVATIVE AND METHOD FOR PRODUCING THEREOF | HIRATAKE, GOU (JP) | 2009-06-25 | — | — | US | disclosed |
| WO-2008137446-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASE | TRUSTEES OF BOSTON UNIVERSITY (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163725-A1 | PHOSPHONIC ACID DIESTER DERIVATIVE AND METHOD FOR PRODUCING THEREOF | PPA1, G6PD, PHOSPHO1 | OPRK1 4159/4885KYNU 2527/4885ELANE 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.